Viewing Study NCT06825728


Ignite Creation Date: 2025-12-26 @ 10:34 AM
Ignite Modification Date: 2025-12-31 @ 7:36 PM
Study NCT ID: NCT06825728
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-02-13
First Post: 2025-02-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Metoprolol in Patients With HFrEF and COPD
Sponsor: Xiangya Hospital of Central South University
Organization:

Study Overview

Official Title: Metoprolol in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of the clinical trial was to see if Metoprolol was effective in treating patients with heart failure and chronic obstructive pulmonary disease. It will also learn about the safety of Metoprolol. The main questions it aims to answer are:

Did Metoprolol reduce the frequency of all-cause deaths and re-hospitalizations in subjects? What medical problems do participants experience after taking Metoprolol? The researchers will compare different doses of Metoprolol to see the best dose for Metoprolol.

Participants will:

Take Metoprolol 23.75mg/ day or the maximum tolerable dose of Metoprolol daily for 24 months.

Regular outpatient follow-up visits to the research center. Their symptoms and Metoprolol dosage were recorded.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2022YFC2010004 OTHER_GRANT National key research and development plan View